Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 205 clinical trials
None
TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia

The purpose of this study is to test whether giving tranexamic acid to patients receiving treatment for blood cancers reduces the risk of bleeding or death, and the need for platelet transfusions. Patients will be randomised to receive tranexamic acid (given intravenously through a drip, or orally) or a placebo.

cancer
cell transplantation
tranexamic acid
hematologic malignancy
  • 682 views
  • 29 Sep, 2021
  • 28 locations
None
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

patients. Quality of Life (QoL) is mainly deteriorated by anemia and by the limitations associated with thrombocytopenia, neutropenia and transfusion dependence. The only available treatment for severe

colony stimulating factor
bone marrow procedure
lenalidomide
hysterectomy
platelet transfusion
  • 19 views
  • 23 Jan, 2021
  • 82 locations
None
A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)

This is a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/L on two counts no sooner than 7 days apart in the 15 days before …

platelet count
autoimmune thrombocytopenia
thrombocytopenia
  • 450 views
  • 23 Jul, 2021
  • 64 locations
None
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

This is a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/L (and no single platelet count >35,000/L) on two counts at least 5 days apart in the 14 days before treatment begins. Patients will receive rilzabrutinib or placebo 400mg …

igiv
neutrophil count
thrombocytopenia
platelet count
kidney function tests
  • 30 views
  • 09 Nov, 2021
  • 84 locations
None
A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)

This is a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/μL on two counts no sooner than 7 days apart in the 15 days before …

platelet count
thrombocytopenia
  • 1 views
  • 05 Nov, 2021
  • 28 locations
None
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

This is a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Patients will receive rilzabrutinib or placebo 400mg …

igiv
neutrophil count
thrombocytopenia
platelet count
kidney function tests
  • 0 views
  • 05 Nov, 2021
  • 86 locations
None
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal Pancreatic or Colorectal Cancer

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer

  • 143 views
  • 25 Nov, 2021
  • 199 locations
None
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Ovarian Cancer or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy

  • 21 views
  • 20 Oct, 2021
  • 175 locations
None
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

thrombocytopenia (platelet count <50,000/L). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or to P/C therapy (approximately 116 patients

ruxolitinib
ct scan
pacritinib
thrombocytosis
essential thrombocythemia
  • 506 views
  • 16 Oct, 2021
  • 179 locations
None
A First in HumanTrial to Evaluate The Safety Tolerability And Pharmacokinetics Of PF-06755347

This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult male subjects. The pharmacokinetics and pharmacodynamics will also be evaluated.

cancer
administered intravenously
malignancy
heart failure
  • 170 views
  • 29 Sep, 2021
  • 6 locations